Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

20071,918 citationsJournal Articlebronze Open Access

Authors

Marilyn J. Manco‐Johnson · University of Colorado Health

Thomas C. Abshire

M L Manco-Johnson · University of Colorado Health

Sharon Funk

Linda Jacobson

Leonard A. Valentino

Abstract

Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).

Topics & Keywords

Hemophilia Treatment and Research Blood Coagulation and Thrombosis Mechanisms Platelet Disorders and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 357, Issue 6, pp. 535-544

DOI: 10.1056/nejmoa067659

Field-Weighted Citation Impact: 34.01